Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Assets (2022 - 2025)

Corvus Pharmaceuticals has reported Current Assets over the past 4 years, most recently at $66.9 million for Q3 2025.

  • Quarterly results put Current Assets at $66.9 million for Q3 2025, up 55.97% from a year ago — trailing twelve months through Sep 2025 was $66.9 million (up 55.97% YoY), and the annual figure for FY2024 was $54.4 million, up 94.62%.
  • Current Assets for Q3 2025 was $66.9 million at Corvus Pharmaceuticals, down from $75.8 million in the prior quarter.
  • Over the last five years, Current Assets for CRVS hit a ceiling of $75.8 million in Q2 2025 and a floor of $22.9 million in Q1 2024.
  • Median Current Assets over the past 4 years was $45.5 million (2025), compared with a mean of $47.3 million.
  • Biggest five-year swings in Current Assets: plummeted 44.77% in 2023 and later skyrocketed 99.08% in 2025.
  • Corvus Pharmaceuticals' Current Assets stood at $43.7 million in 2022, then crashed by 35.97% to $28.0 million in 2023, then skyrocketed by 94.62% to $54.4 million in 2024, then increased by 23.04% to $66.9 million in 2025.
  • The last three reported values for Current Assets were $66.9 million (Q3 2025), $75.8 million (Q2 2025), and $45.5 million (Q1 2025) per Business Quant data.